The "Thrombocytopenia - Global Clinical Trials Review, 2025" has been added to ResearchAndMarkets.com's offering. This extensive report offers key top-line data concerning ongoing Thrombocytopenia ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...

“Although shareholder rights plans are generally viewed with caution by investors and Glass Lewis, particularly in the context of public shareholder dissent, the facts of this case do not, in our view ...

With its existing entitlement, plus the newly acquired economics from BioInvent, XOMA Royalty will be entitled to milestones of up to USD $16.25 million from Takeda and mid-single digit royalties on ...

A new combination therapy that pairs a radiopharmaceutical (177Lu-DOTATATE) with a DNA-repair blocker (olaparib) has been ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

Regeneron (REGN) announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors – carfilzomib or ...

The results emphasize the importance of PARP inhibitors in BRCA-mutated breast cancer, particularly in triple-negative breast ...

In a recent study, a research team led by Professor Hyun Hye-kyung and Professor Heo Cheol-woong of Yonsei University's ...

A new study identifies eight domains of active systemic #lupus erythematosus for defining meaningful treatment response in ...

COIMBATORE: In response to the sudden surge in fever cases in the hilly region of Valparai in Coimbatore district, the health ...